Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 881 participants.
Also called NCT01819129
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 881 participants
- Sponsor
- Registry
-
NCT01819129 -
2010-024051-93 -
CTRI/2014/01/004285
-
- Main results
- Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Croatia, India, Israel, Puerto Rico, Russia, Serbia, Slovakia, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01819129. Randomized; double masking; primary purpose treatment. Start 2013-09-09 (actual); primary completion 2015-01-22 (actual). Results posted on 2017-12-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
- Acronym
- onset® 2
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Faster-acting insulin aspart
- Intervention (Drug)
- Insulin aspart
- Intervention (Drug)
- Insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01819129- Content hash
d0565dc4a18db0de27fc17bcb65d03e917bd8e896202d436cd162039512c990e